Amplify Alternative Harvest ETF (MJ)

Treating the Cannabis Industry as a Legitimate Sector
Industry leaders reported that the Trump administration increasingly engaged with cannabis businesses the same way it does with other regulated industries. This shift helped reduce stigma and encouraged investment and innovation. $MJ

Trump’s rescheduling push triggered a broader federal review
The DEA is now running an expedited hearing (starting June 29, 2026) to consider moving all marijuana from Schedule I to Schedule III, which would reduce tax burdens (280E), expand research, and legitimize state programs. This is also considered bullish for the sector. $MJ

🌱 $MJ — Focus: Global Cannabis & Hemp Exposure
A fund that provides broad exposure to companies operating in the legal cannabis and hemp industries across multiple countries.

$MJ — ETFMG Alternative Harvest ETF
$MJ remains the largest and most recognized cannabis ETF — a sector benchmark that moves fast when momentum returns.

• Broadest exposure across U.S. MSOs, Canadian LPs, tobacco partners, and ancillary plays
• Liquidity advantage vs. smaller ETFs
• Captures catalysts like rescheduling, banking reform, and state-level expansion
• Cannabis + tobacco crossover adds stability and optionality
• Trades near multi-year lows, giving it major snapback potential

When cannabis heats up, $MJ is usually one of the first ETFs to move.

$MJ MJ – Amplify Alternative Harvest ETF
What it really focuses on

MJ is one of the oldest and best-known cannabis ETFs and is heavily tilted to Canadian LPs and global cannabis equities:

Top holdings include: TLRY, Cronos, Canopy Growth, SNDL, Village Farms, Aurora, High Tide, Organigram. TLRY is one of the largest positions by weight.

It also holds some ancillary and cash/treasury instruments, but the core is still LPs and cannabis-adjacent equities.

Why those stocks?

Legacy listing advantage: Canadian LPs were among the first cannabis names to list on major exchanges, so they became the natural core of early cannabis indices and ETFs like MJ.

Global optionality: LPs like TLRY, Cronos, and Canopy have international medical operations and partnerships, giving exposure to non-U.S. legalization trends.

Brand and CPG angle: TLRY and Canopy in particular are trying to pivot into branded consumer products (beverages, wellness, etc.), which MJ captures by holding them at size.

Market demand angle

Who buys MJ? Investors who want a simple, liquid, “brand-name” cannabis ETF and are okay with a big Canadian tilt.

Demand drivers:

Retail investors who recognize names like TLRY and CGC.

International investors who can more easily access Canadian LPs than U.S. MSOs.

Implication for TLRY: Because MJ is widely recognized, flows into or out of MJ can materially affect TLRY’s trading, given TLRY’s large weight in the fund.

🍺 Alcohol Use in Wartime
Alcohol consumption historically rises during major conflicts, especially among soldiers and civilians under stress.

Why alcohol use increases
Stress, trauma, and uncertainty drive people toward coping behaviors.

Availability: Alcohol is usually legal and easier to obtain than illicit drugs.

Cultural norms: Drinking has long been embedded in military culture.

Evidence
Deployment is associated with unhealthy drinking and risky behaviors among service members.

Binge drinking rates in the military are higher than in the general population, even though other drug use is low.

🌿 Cannabis (Weed) Use in Wartime
Cannabis use does not reliably increase during wartime—at least not among active-duty troops.

Why cannabis use doesn’t rise in the military
Zero-tolerance policies

Mandatory drug testing

Severe penalties, including dishonorable discharge

Stigma around seeking help, which can discourage any behavior that risks detection

Evidence
Illicit drug use among active-duty personnel is under 1%, far lower than civilian rates.

Even though cannabis is widely used in civilian life, military enforcement keeps usage extremely low.

After service
Veterans sometimes show higher rates of substance use disorders, including cannabis, once they leave the military and lose those restrictive controls.

🧭 Civilian Populations During War
Outside the military, patterns vary:

Alcohol use tends to rise due to stress, scarcity, and social disruption.

Cannabis use depends on local laws, availability, and cultural norms.

In modern conflicts, where cannabis is legal in many regions, civilian use may increase—but this is context-dependent and not as well documented.

🧩 Bottom Line
Alcohol: Usually increases during wartime across both military and civilian populations.

Cannabis:

Active-duty military: Stays very low due to strict enforcement.

Civilians: Varies widely; may increase, but evidence is inconsistent. $MJ $CGC $TLRY

Sector-Wide Momentum on U.S. Banking & Reform Headlines
Search results show CGC moves sharply on U.S. policy news — including cannabis banking reform discussions.

Why it matters:
CGC is one of the most liquid cannabis stocks, so traders often use it as a proxy for the entire sector.

🌿 Medical marijuana is a rapidly expanding global industry with demand accelerating and the market projected to reach tens of billions of dollars.
The medical cannabis market has grown from roughly $14 billion in 2022 to more than $20 billion by 2025, with forecasts projecting it to reach $65 billion by 2032 and, under more aggressive models, potentially over $190 billion by 2034. Demand continues rising due to broader medical acceptance, expanding legalization, increased physician adoption, and growing use for chronic pain, cancer-related symptoms, neurological conditions, and other therapeutic applications. As more countries open medical programs and product formats diversify, the industry’s long-term growth trajectory remains one of the strongest in the global health and wellness sector. $MJ $TOKE $TLRY $CGC $CRON

🌿 Global Cannabis Market
The worldwide cannabis and hemp sector was valued at about $38 billion in 2025.

It is expected to grow to around $49 billion in 2026, $61 billion in 2027, and could reach over $400 billion by 2035.

This reflects an exceptionally strong long-term growth rate of about 26% per year through 2035.

Growth is driven by expanding legalization, rising recreational use, and broader industrial hemp applications.

🏥 Medical Cannabis Market
The medical cannabis segment was worth about $30.6 billion in 2025.

It is projected to rise to $37.6 billion in 2026 and could reach nearly $196 billion by 2034.

This segment is growing at roughly 23% per year, fueled by increasing medical acceptance and use in treating chronic pain, epilepsy, cancer-related symptoms, and neurological conditions.

💧 CBD (Cannabidiol) Market
Multiple independent forecasts give a consistent picture:

The CBD market is valued at around $10–12 billion in 2025–2026.

Depending on the model, it is expected to reach $24–45 billion between 2031 and 2035.

Growth rates range from about 14% to 16% per year.

Demand is driven by wellness products, anxiety and sleep support, pain relief, and the dominance of hemp-derived CBD in North America.

🌱 Hemp Market
The search results do not provide a standalone global dollar value for hemp.

However, they confirm that hemp is the primary source for CBD production and is expected to expand rapidly as demand for CBD, industrial fibers, bioplastics, textiles, and construction materials increases.

Hemp’s growth trajectory closely follows the CBD market and the broader cannabis sector.

📈 Overall Demand Outlook (2026–2035)
Across all categories—cannabis, medical cannabis, CBD, and hemp—the global market is experiencing strong double-digit annual growth.
Key forces behind rising demand include:

Ongoing legalization in major regions

Medical adoption for chronic and severe conditions

Expansion of wellness and therapeutic CBD products

Industrial uses of hemp in manufacturing and sustainable materials

Innovation in cultivation, extraction, and product development $MJ

$MJ (ETFMG Alternative Harvest ETF)
Regulatory Catalyst
U.S. cannabis rescheduling reduces tax burdens and opens the door for broader institutional participation, directly benefiting ETF constituents.

Diversified Exposure
$MJ provides access to global cannabis operators, ancillary businesses, and related industries, spreading risk while capturing sector-wide upside.

Institutional Accessibility
As a liquid ETF, $MJ offers funds and retail investors a regulated vehicle to gain cannabis exposure without single-stock risk.

Global Market Growth
Cannabis legalization continues to expand internationally, driving revenue growth across holdings.

Margin Expansion Potential
Scaled operators within $MJ are positioned to improve profitability as tax burdens ease and economies of scale kick in.

M&A Consolidation
Constituents are actively pursuing acquisitions, creating stronger players with pricing power and national footprints.

Volatility Advantage
Cannabis stocks’ elevated volatility creates opportunities for options and algo-driven trading strategies tied to $MJ.

Technical Setup
Chart signals show accumulation zones and breakout potential, aligning with algorithmic buy triggers.

Correlation Edge
Cannabis equities often trade independently of broader indices, offering diversification benefits for quant portfolios.

Policy Momentum
Federal banking reform and executive actions act as sentiment catalysts, sparking rallies amplified by algorithmic trading.

West Virginia State Senator Tom Takubo (R) filed legislation that would reschedule cannabis under state law, moving it to Schedule III. $MJ $TLRY $CGC

$MJ $WEED $CGC analysts note a bullish technical pattern emerging, suggesting potential rebound opportunities for traders.

$TLRY is at all time bottom low, all the other cannabis stocks are very stable and have been for weeks as Tilray has bottomed $MJ

.

🌟 Optimistic Outlook for Tilray
1. Policy Shifts in Cannabis
A major driver would be changes in U.S. federal law. If cannabis is legalized or reclassified, Tilray could suddenly gain access to banking services, interstate trade, and a much larger consumer base.

Similar moves in Europe, especially Germany, could spark a domino effect across the EU, giving Tilray a strong foothold in international markets.

2. Strategic Growth Moves
Tilray has been diversifying into alcohol and craft beverages. If cannabis and alcohol distribution channels merge, it could create a powerful hybrid business model.

Expansion through acquisitions or partnerships in the U.S. would strengthen its presence and broaden revenue streams.

3. Financial Improvements
Investors would turn more positive if Tilray shows consistent profitability and trims down its debt load.

Demonstrating operational efficiency and sustainable margins would shift sentiment from speculative to growth-oriented.

4. Market Psychology
Tilray has a history of being a retail trader favorite. Any legalization headline could ignite a surge similar to past meme-stock rallies.

Renewed interest from institutional investors and ETFs could provide steady demand for shares.

📈 Potential Price Trajectories
Moderate upside: $90–$100 (post-split) if profitability aligns with regulatory progress.

Strong upside: $120–$150 (post-split) if U.S. legalization arrives quickly and Tilray capitalizes on it.

Aggressive upside: $200+ (post-split) only if legalization coincides with Tilray becoming a dominant global player across cannabis and alcohol.

⚡ Big Picture
Tilray’s bullish path is tied almost entirely to legal and regulatory breakthroughs. Without them, fundamentals alone won’t justify a triple-digit run. But if legalization momentum builds, Tilray’s scale and international reach could make it one of the biggest beneficiaries. $MJ $TLRY

Diversified Cannabis Exposure $MJ is one of the first and largest cannabis-focused ETFs, giving investors broad exposure to global cannabis companies without betting on a single stock.

Global Reach Unlike U.S.-only ETFs, $MJ includes companies from Canada, the U.S., and international markets, capturing growth across multiple jurisdictions.

Access to Leading Names Holdings include major players like Tilray, Canopy Growth, Cronos, and other well-known cannabis firms, offering investors a basket of sector leaders.

Benefit from Legal Reform Any progress on U.S. cannabis reclassification, legalization, or banking reform could lift the entire sector — and $MJ provides a direct way to capture that upside.

Risk Mitigation Through Diversification Individual cannabis stocks can be volatile. $MJ spreads risk across dozens of companies, reducing exposure to single-company setbacks.

Institutional Credibility As one of the earliest cannabis ETFs, $MJ has brand recognition and credibility among investors looking for a regulated way to invest in the sector.

Consumer Demand Growth Cannabis consumption continues to rise globally, both for medical and recreational use, providing a strong demand base for ETF constituents.

Political Catalysts Discussions around cannabis rescheduling and bipartisan support for reform bills have fueled optimism, and $MJ is positioned to benefit from sector-wide rallies.

Liquidity & Accessibility $MJ trades on a major U.S. exchange, making it easy for retail and institutional investors to gain cannabis exposure without dealing with OTC stocks.

Long-Term Industry Upside Cannabis is still in the early stages of global legalization. $MJ offers a simple, diversified way to ride the long-term growth wave.

📈 The Bullish Case Summarized
$MJ is essentially a basket play on cannabis reform and global industry growth. By pooling leading cannabis companies across multiple regions, it gives investors diversified exposure to a sector with explosive potential if legalization advances. For those bullish on cannabis policy change, $MJ is one of the most straightforward vehicles to capture upside. $MJ

Banking Reform Trump signaled support for safe banking laws, potentially opening the door for cannabis businesses to access traditional financial services. $MJ $TLRY $CGC

Interesting - Parkinson's Patient tries Marijuana for the First Time https://www.youtube.com/shorts/h4mlkLcwpAM $MJ

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176819221 $MJ $MJNA

$MJ Medical marijuana isn’t just medicine—it’s a lifeline for millions fighting chronic illness. Rescheduling unlocks access, research, and a booming new tax revenue stream for America’s future. 💊💰🇺🇸

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176686337 $MJ

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176656801 $MJ

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176647753 $MJ $CGC

SB6 has passed the Texas senate! SB6 has passed the Texas senate!

Now the bill moves onto the house, just like SB3 and SB5, before moving onto the governor.

This wasn’t very surprising considering the control the Lt. Gov has on the senate, so we’ll move onto the house and keep fighting for regulation there!… pic.twitter.com/VQ92YBRlNs— Hometown Hero ATX (@HometownHeroATX) August 19, 2025 $MJ $TLRY $CGC

How Trump is making pot a MAGA issue
https://www.axios.com/2025/08/13/trump-marijuana-policy-maga-democrats $MJ

$TLRY $MJ

$TLRY Tilray Brands is a STRONG BUY at SeekingAlpha https://seekingalpha.com/article/4767975-tilray-brands-is-now-a-strong-buy $MJ

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176059202 $MJ

Senate Banking Committee Witness Urges Members to Improve, Pass SAFE Banking Act https://www.cannabisbusinesstimes.com/safe-banking-act/news/15736710/senate-banking-committee-witness-urges-members-to-improve-pass-safe-banking-act $MJ

Trump Ally Who Lobbies For Marijuana Industry Predicts Rescheduling And Banking Will Get Done Under New Administration https://marijuanamoment.net/trump-ally-who-lobbies-for-marijuana-industry-predicts-rescheduling-and-banking-will-get-done-under-new-administration-but-not-legalization/ $MJ

Canopy Growth and Acreage Confirm Canopy USA's Completed Acquisition of Acreage
https://www.prnewswire.com/news-releases/canopy-growth-and-acreage-confirm-canopy-usas-completed-acquisition-of-acreage-302325668.html $MJ

Hemp, Inc. provides industrial hemp in the United States. The company offers pre-roll blends, fortified pre-rolls; Bubba Kush hemp; caviar/moon rocks; and diamonds and crumbles. It is also involved in the processing and farming industrial hemp; extracting hemp CBD oil; and provides education seminar for farmers and entrepreneurs, as well as provides research and development, and hemp consulting. In addition, the company sells its products under the King of Hemp brand. The company was formerly known as Marijuana, Inc. and changed its name to Hemp, Inc. in June 2012. Hemp, Inc. was incorporated in 2008 and is based in Las Vegas, Nevada. $MJ $HEMP

https://www.marijuanamoment.net/feds-to-weigh-40000-marijuana-rescheduling-comments-from-governors-lawmakers-health-experts-and-advocates/

Volume. Marijuana sector turn on this election season. $MJ

Was $45 let's get back to double digits

Back and fill over tommorow i bet. Calling a bottom this week. Buying select issurers

Until Friday.

Recovering ...

MJ never broke $3.00

The weekly chart is beautiful. Just starting to curl up. I believe it should hit the 50 SMA. Was over $27 two years ago. Whole markets been smoked and when reverses should reverse pretty nice for a few imo

$3.02
+0.015(+0.50%)

American Index

The cannabis sector trying to bottom. It would help if Tilray and Canopy stop falling. Added to OGI. Swapping out MJ for MSOS.

Complacency ---> ~$80
https://finviz.com/published_idea.ashx?t=IWM&f=053023&i=IWMm163006935i

If the DOW closes green today, Cannabis MUST do the same! We have got to shake off the TILRAY hangover.

I never received an unsafe product before it was "legal"!

After they default, because they will never be able to pass that deal, they will have no taxing authority due to their criminal acts!

Super important week.

MJ $3.07

I expect MJ to hold $3.00 and produce a confirmed reversal within the next 21 days.

SAFE BANKING ACT 2023

MJ OUTLOOK 2023

ETF MJ

Really need a green Dow Jones on Tuesday. With that, Cannabis should be green. Not sure if there will be another shoe to drop similar to TLRY on Friday.

Nice yea this sector seems oversold for sure i agree